

## **DISPOSAL OF INVESTMENT IN CRYOVIVA SINGAPORE PTE. LTD.**

---

### **INTRODUCTION**

The Board of Directors (the “**Board**”) of AsiaMedic Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that the Group’s wholly-owned subsidiary, AsiaMedic CytoLife Pte. Ltd. (“**ACPL**”), has entered into a sale and purchase agreement dated 29 March 2016 (the “**SPA**”) to dispose of its entire shareholding interest of 502,266 ordinary shares, representing 15.24% in Cryoviva Singapore Pte. Ltd. (“**CSPL**”), to Arctic Overseas Pte. Ltd. (the “**Purchaser**”) for a cash consideration of S\$50,000 (the “**Disposal**”).

### **INFORMATION ON CSPL AND RATIONALE FOR THE DISPOSAL**

CSPL was incorporated on 26 July 2013 and carries on the business of cord blood and stem cell banking in Singapore. ACPL and Cryoviva International Pte Ltd hold 15.24% and 84.76%, respectively, of the issued shares in CSPL. CSPL has been incurring losses since its inception. It is expected that CSPL will continue to require fund contributions from its shareholders. In addition, cord blood and stem cell banking is not a core business of the Group. Having taking into account these considerations, the Group has decided to divest of its shares in CSPL.

### **CONSIDERATION FOR THE DISPOSAL**

The consideration of S\$50,000 was arrived at on a willing buyer and willing seller basis, after taking into account various factors including the cost of investments by the Group and the current financial position of CSPL. The Group has been equity accounting for its share of CSPL’s losses. As a result, the Group’s cost of investment in the company has been fully written off and the carrying value of the Group’s investment in CSPL is zero as at 31 December 2015. After taking into account expenses in relation to the Disposal, the Disposal will result in net gain of approximately S\$48,000 to the Group. No valuation of CSPL has been commissioned. The Disposal will enable the Group to realise some returns from its investment in CSPL.

### **FINANCIAL EFFECTS**

The transaction is not expected to have a material effect on the earnings or net tangible assets per share of the Group for the financial year ended 31 December 2015, assuming that the transaction had been effected at the beginning or end of that financial year respectively.

## RELATIVE FIGURES COMPUTED ON THE BASES SET OUT IN RULE 1006

The relative figures computed on the bases set out in Rule 1006 of the Listing Manual Section B: Rules of Catalyst (“**Catalist Rules**”) of the Singapore Exchange Securities Trading Limited are as follows:

- |  |   |
|--|---|
| (a) The net asset value of the assets to be disposed of, compared with the group's net asset value. This basis is not applicable to an acquisition of assets.                          | Based on the zero carrying value of the investment and the Group's net asset value of S\$12.2 million as at 31 December 2015, the relative figure is zero percent.  |
| (b) The net profits attributable to the assets acquired or disposed of, compared with the group's net profits.   | Based on the share of loss incurred by CSPL of S\$250,000 and the Group's loss before income tax of S\$1,873,000 for the year ended 31 December 2015, the relative figure is approximately 13.3%.   |
| (c) The aggregate value of the consideration given or received, compared with the issuer's market capitalisation based on the total number of issued shares excluding treasury shares. | Based on the consideration of S\$50,000 and the Company's market capitalisation of approximately S\$26.2 million (determined by multiplying the total number of issued shares of Company (excluding treasury shares) of 390,488,125 shares and the volume-weighted average price of the Company's shares of S\$0.067 on 28 March 2016, being the market day preceding the date of the Agreement), the relative figure is approximately 0.19%. |
| (d) The number of equity securities issued by the issuer as consideration for an acquisition, compared with the number of equity securities previously in issue.                       | Not applicable as not an acquisition.   |
| (e) The aggregate volume or amount of proved and probable reserves to be disposed of, compared with the aggregate of the group's proved and probable reserves.                         | Not applicable as not a mineral, oil and gas company.   |

As the relative figure for Rule 1006(b) above exceeds 5% but is less than 50%, the Disposal constitutes a discloseable transaction under Chapter 10 of the Catalist Rules.

## INTEREST OF DIRECTORS AND CONTROLLING SHAREHOLDERS

None of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the transaction, other than through their shareholdings in the Company (if any).

## DOCUMENT FOR INSPECTION

The SPA will be available for inspection during normal business hours at the Company's registered address at 350 Orchard Road, #08-00 Shaw House, Singapore 238868 for three (3) months from the date hereof.

## FURTHER UPDATES

The Company will release such further announcements as may be necessary and/or appropriate to update shareholders of any material updates to the Disposal.

## BY ORDER OF THE BOARD

**Ms Foo Soon Soo**  
**Company Secretary**

29 March 2016

*This announcement has been prepared by the Company and reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.*

*Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd)  
Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805  
Telephone number: (65) 6319 4954*